Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals declining financial metrics, such as a decrease in income and EPS, alongside deceleration in software bookings and unclear management responses regarding growth targets. Despite some positive aspects like AI integration and regulatory tailwinds, the overall sentiment is negative due to the financial underperformance and cautious guidance, leading to a likely negative stock price reaction.
Key Financial Performance
Total Revenue (Q4 2025) $103.6 million, representing year-over-year growth of 3% on a reported basis and 2% on a constant currency basis. Growth attributed to MIDD software and Pinnacle 21.
Total Revenue (Full Year 2025) $418.8 million, representing year-over-year growth of 9% on a reported basis and 8% on a constant currency basis. Growth driven by software and services performance.
Software Revenue (Q4 2025) $46.4 million, increased 10% over the prior year period on both reported and constant currency basis. Growth driven by MIDD software and Pinnacle 21.
Software Revenue (Full Year 2025) $183.3 million, grew 18% on both reported and constant currency basis. Organic software growth was 7%, in line with the plan. Chemaxon contributed $22.9 million to reported software revenue.
Services Revenue (Q4 2025) $57.3 million, down 1% versus the prior year period on both reported and constant currency basis. Decline attributed to regulatory writing revenue decrease.
Services Revenue (Full Year 2025) $235.6 million, grew 3% on both reported and constant currency basis. Regulatory writing revenue was $50.4 million, down from $54.7 million in 2024.
Adjusted EBITDA (Q4 2025) $32.5 million, decreased from $33.5 million in Q4 2024. Adjusted EBITDA margin was 31%, in line with expectations.
Adjusted EBITDA (Full Year 2025) $134.5 million, increased from $122 million in 2024. Adjusted EBITDA margin remained consistent at 32%.
Net Loss (Q4 2025) $5.9 million compared to net income of $6.6 million in Q4 2024. Loss attributed to higher employee-related expenses and increased R&D investments.
Adjusted Net Income (Q4 2025) $14.9 million compared to $24.7 million in Q4 2024. Decline due to higher operating expenses.
Diluted Loss Per Share (Q4 2025) $0.04 compared to earnings of $0.04 per share in Q4 2024. Loss driven by increased costs.
Adjusted Diluted Earnings Per Share (Q4 2025) $0.09 compared to $0.15 in Q4 2024. Decline due to higher operating expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-enabled technology and model-informed drug development platforms: Certara is leveraging AI-enabled technology and model-informed drug development platforms to transform the life science industry. These platforms are deeply embedded in industry workflows and utilized by regulatory bodies.
New methodologies in drug development: Certara is focusing on computational modeling and model-informed approaches to improve clinical trial designs, reduce costs, and accelerate timelines. Examples include using QSP simulations to prioritize drug candidates and virtual populations for rare disease research.
Market opportunity in life sciences: Certara sees a compelling market opportunity to transform innovation in life sciences, driven by regulatory acceptance of technological solutions and the pharmaceutical industry's need to reduce development costs and timelines.
Global customer base: Certara has over 2,600 customers and 23 regulatory agencies worldwide using its technologies, showcasing its strong market presence.
Operational improvements: Certara is implementing operational changes to sharpen execution, focus investments, and improve customer engagement. This includes a $10 million cost avoidance plan for 2026.
Integration of software and services: Certara is enhancing its integration of software products with scientific expertise to create an innovation flywheel and improve customer relationships.
Strategic priorities: Certara is focusing on a more customer-centric operating model, accelerating AI integration, and improving operational efficiency to drive growth.
Regulatory writing and operations business review: Certara is in the final stages of a strategic review of its regulatory writing and operations business to maximize shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Acceptance of AI-enabled Technology: The true potential and market acceptance of AI-enabled technology, data, and model-informed drug development has yet to be achieved, which could limit growth opportunities.
External Market Conditions: External market conditions have created headwinds, including customer reorganizations, reprioritizations, slower clinical trial completions, and weaker pipeline conversion of new and renewal software.
Internal Execution Gaps: Internal execution gaps have impacted results, including challenges in converting R&D investments into sustained organic growth and improving sales and go-to-market strategies.
Software Bookings Performance: Software bookings were lower than expected, particularly among Tier 1 and Tier 2 customers, due to external factors and execution challenges.
Regulatory Writing Business Uncertainty: The company is in the final stages of a strategic review of its regulatory writing and operations business, creating uncertainty about its future direction.
Operational Efficiency: Certara must improve operational efficiency, including sharpening pricing, improving delivery, and driving higher returns from investments in sales, marketing, and R&D.
Cost Management: The company has identified $10 million in cost avoidance for 2026, but achieving this requires disciplined execution.
Revenue Growth Challenges: Certara is guiding to flat to low single-digit revenue growth for 2026, reflecting both market conditions and operational improvements that need to be implemented.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Certara is guiding to flat to low single-digit revenue growth for 2026, reflecting both market conditions and planned operational improvements.
Cost Management: The company has identified a path to approximately $10 million in cost avoidance relative to the initial 2026 plan.
Adjusted EBITDA Margin: Expected to be in the range of 30% to 32% for 2026, with margins lower in the first half of the year and increasing in the second half.
Adjusted EPS: Expected to be in the range of $0.44 to $0.48 per share for the full year 2026.
Capital Deployment: Certara plans to execute against its existing share repurchase authorization and be strategic with capital deployment.
Operational Focus: Certara will focus on accelerating AI integration, enhancing customer engagement, and improving operational efficiency to drive growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made during the call.
Share Repurchase Program: Certara repurchased approximately 3.3 million shares for $43 million during 2025. The company also intends to execute against its existing share repurchase authorization in 2026, viewing it as a compelling long-term investment at current levels.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What attracted Jon Resnick to Certara and how does he view the differentiation of Certara's software products and talent?
A:Jon Resnick was attracted to Certara due to its position in the market, the inefficiencies in pharma R&D spend, and the company's strong assets and tools. He views Certara's software products as highly differentiated and deeply embedded in customer workflows, with strong relationships with regulators and a high track record of validation and transparency. He also sees the services side as reinforcing the software, creating a strong proposition when combined.
Q:How does a platform approach, cross-selling, and integrating workflows factor into Certara's strategy?
A:Jon Resnick stated that there is no radical shift in strategy. The focus will be on serving daily users while building functionality and engagement at senior levels to accelerate regulatory timelines and development. The strategy includes developing product enhancements and stitching together assets to ensure capabilities move across different stages of development.
Q:What is the breakdown of Certara's revenue guidance for 2026 and the factors influencing it?
A:Certara's revenue guidance for 2026 is 0% to 4% growth. Services revenue has been in low single-digit growth, with a strong Q4 pipeline surge. Software revenue grew 10% in Q4 but saw deceleration in bookings. The tight correlation between bookings and revenue, combined with low single-digit services growth, results in the flat to 4% growth expectation.
Q:What factors influenced the deceleration in software bookings in Q4?
A:Factors include big pharma reprioritizing headcount reductions, study counts being down (affecting products like Pinnacle 21), and execution issues where pipeline visibility did not convert as expected. There is also a lag in seat licensing tied to study reductions from previous years.
Q:What are Certara's plans and opportunities in AI enablement?
A:Certara is embedding AI into core software assets like Phoenix and launching AI-driven products such as CertaraIQ. AI is also being used to accelerate internal software development and improve operational efficiency. The company sees opportunities to enable services and improve infrastructure, driving both short-term and mid-term productivity gains.
Q:What are the efforts underway to revamp Certara's commercial organization?
A:Efforts include optimizing customer relationships, improving pricing and contracting, targeting sales initiatives with AI-driven productivity, and ensuring the right people are in the right roles. Low-hanging fruit includes pricing and customer centricity initiatives, while medium-term efforts focus on transforming client relationships.
Q:What is the outlook for software bookings and services growth in 2026?
A:Certara does not expect Q1 2026 to recover the pipeline conversion issues from Q4 2025. Growth acceleration is expected in subsequent quarters due to easier comparisons and increased conversion. Services growth is seen as a leading indicator of market stability and potential discretionary spend increases.
Q:What is Certara's approach to pricing and aligning price with value?
A:Certara is exploring more disciplined pricing strategies for certain products and aligning pricing with the value provided to clients. The company aims to partner with clients in a longitudinal way, demonstrating cost avoidance, timeline acceleration, and trial risk reduction to justify pricing adjustments.
Q:What is Certara's view on the FDA's regulatory changes and their impact?
A:Certara sees the FDA's push towards computational and modeling-based approaches as a tailwind for its offerings. While changes take time to materialize, the company is seeing leading indicators in its QSP and PBPK services, reflecting growing acceptance of these approaches.
Q:What are Certara's plans for achieving double-digit growth over time?
A:Certara aims to achieve double-digit growth by leveraging market opportunities, improving execution, and focusing on core growth areas like biosimulation and computational work. The company plans to provide a clear multiyear growth path in upcoming quarters.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear timeline or specific benchmarks for achieving double-digit growth, stating that they would provide more details in future quarters. Additionally, they did not fully address how AI might influence customer decision-making or the exact impact of FDA regulatory changes on client behavior.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI technology
MIDD
approval
avenue
care
client
combination
core
credibility
decision making
design
development line
discipline
disease
dose
employee
engagement
expertise
improvement
level
life science
market acceptance
market condition
market plan
mission
model approach
need
perspective
population
potential market
priority
product portfolio
relationship
relevance
research
science industry
shareholder value
strength
technology model
technology service
urgency
use case
workflow
CERT Transcript
Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call reveals declining financial metrics, such as a decrease in income and EPS, alongside deceleration in software bookings and unclear management responses regarding growth targets. Despite some positive aspects like AI integration and regulatory tailwinds, the overall sentiment is negative due to the financial underperformance and cautious guidance, leading to a likely negative stock price reaction.
Certara, Inc. (CERT) Presents at Stephens Annual Investment Conference 2025 Transcript
Neutral11-18
Certara, Inc. (CERT) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
Certara, Inc. (CERT) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call revealed strong financial performance, with positive EPS growth and a solid cash position. Despite some deceleration in Tier 1 services, the company is optimistic about CertaraIQ's launch and future growth in software sales, driven by AI integration and market demand. The Q&A session highlighted productivity improvements and a favorable software mix, boosting gross margins. While guidance for services is cautious, the overall sentiment is positive, supported by strategic R&D investments and exposure to growing markets. The market cap suggests moderate volatility, aligning with a 'Positive' rating.
CERT Slides
CERT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
